KTRA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients...

Stats
Dagens volum	3.42M
Gjennomsnittsvolum	14.85M
Markedsverdi	8.69M
EPS	$0 ( 2024-02-13 )
Neste inntjeningsdato	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-30	Johnson Laura L.	Buy	8 500	Options (Right to Buy)
2023-08-30	Favorito Tamara A	Buy	8 500	Options (Right to Buy)
2023-08-30	Hoffman Robert E.	Buy	23 142	Options (Right to Buy)
2023-08-30	Toth Robert Joseph Jr	Buy	8 500	Options (Right to Buy)
2023-08-30	Brown Dennis M	Buy	10 175	Options (Right to Buy)

INSIDER POWER
100.00
Last 96 transactions
Buy: 12 848 509 \| Sell: 15 566

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: 0.58 (weak)

Signal:(49.171) Neutral

Kintara Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
CRON	0.925
EVLO	0.918
RPTX	0.904
SLNG	0.901
CFRX	0.899
DRUG	0.898
LVTX	0.897
JAGX	0.895
REYN	0.894
KNSA	0.894

10 Mest negative korrelasjoner
CSLM	-0.923
HERA	-0.911
TBSAU	-0.91
CITE	-0.909
PPYA	-0.906
HERAU	-0.903
FRON	-0.903
ABGI	-0.903
FTAA	-0.901
BYNOU	-0.901

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kintara Therapeutics, Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.64
( weak negative )

0.00
( neutral )

0.57
( weak )

Kintara Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2023
Omsetning:	$0
Bruttogevinst:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2022
Omsetning:	$0
Bruttogevinst:	$-60 000.00 (0.00 %)
EPS:	$-23.22

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-73.97

Financial Reports:

No articles found.

Kintara Therapeutics,

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.